Navigation Links
Encouraging Phase III Study Results Show PET Imaging with Florbetaben Reliably Detects Beta-Amyloid in the Brain
Date:4/15/2012

MUMBAI, India, April 15, 2012 /PRNewswire/ -- Piramal Imaging SA ("Piramal"), a newly formed subsidiary of Piramal Healthcare Limited [NSE: PIRHEALTH, BSE: 500302], announced positive first results from a Phase III study that showed that PET imaging with florbetaben reliably detects beta-Amyloid in the brain during life with great accuracy and thus shows value as a potential tool to aid in the diagnosis and assessment of Alzheimer's disease. The study results will be featured as part of the Emerging Science Program on April 25th at the American Academy of Neurology's 64th Annual Meeting in New Orleans.

(Photo:  http://photos.prnewswire.com/prnh/20120415/NY87619 )

Historically, the only way to definitively diagnose Alzheimer's disease has been after death – at autopsy – through analysis and identification of beta-Amyloid in brain tissue. The global Phase III trial employed a unique and rigorous study design comparing in vivo brain PET imaging with florbetaben to post-mortem analysis of the brain tissue.

All study endpoints were met, and the study showed that PET imaging with florbetaben provided reliable, reproducible results. The visual assessment procedure proposed for routine clinical practice demonstrated 100% sensitivity and 92% specificity with excellent inter-reader agreement (kappa = 0.88).

Piramal has signed an agreement to acquire worldwide rights to the molecular imaging research and development portfolio of Bayer Pharma AG through its newly created subsidiary – Piramal Imaging SA. Florbetaben is the lead compound in the portfolio.

"This is not only an important milestone for florbetaben, but it also marks an important milestone for our company," says Dr. Swati A. Piramal, Director, Piramal Healthcare Limited, "The creation of Piramal Imaging allows us to pursue our mission to increase diagnostic accuracy of serious medical conditions for improved patient outcomes."  Dr. Piramal also serves on the Dean's Advisory Board of both the Harvard School of Public Health and Harvard Business School.

This pivotal trial is the first to overlay MRI and PET data to accurately match florbetaben gray matter uptake with disease in six defined regions of the brain.  This was done to confirm that florbetaben binds to beta-Amyloid on both a regional (brain sections) and subject (whole brain) level. This combination provides considerably more data points than any other beta-Amyloid tracer trial to date. Based on a region-by-region comparison, florbetaben detected beta-Amyloid with a sensitivity of 77% and a specificity of 94% with substantial inter-reader agreement (kappa = 0.66), significantly exceeding the pre-specified threshold, confirming the study hypotheses.

Note to the Editors:

About Florbetaben (BAY 94-9172)

Florbetaben is an 18F-labeled PET tracer that specifically binds to deposition of beta-Amyloid. These depositions (plaques) consist of proteins that accumulate in the brain and are a pathological hallmark of Alzheimer's disease. As the aggregation of the beta-Amyloid protein in the brain is also a key target for new therapeutic treatments under development, florbetaben might also be able to support the development of these new treatment approaches. A Phase II study showed that patients with clinical diagnosis of Alzheimer's disease could be differentiated from age-matched healthy volunteers on the basis of florbetaben uptake pattern in the brain. The results of the Phase II study were presented at the International Conference on Alzheimer's diseases (ICAD) in Vienna, Austria in July 2009 and published in the Lancet Neurology in April 2011.

About Alzheimer's Disease

Alzheimer's disease is a devastating neuro-degenerative disease and the most common cause of dementia. Most cases of Alzheimer's disease affect people over the age of 60. It is a progressive disease that can lead to premature death. In 2006, estimates suggested that more than 26 million people worldwide were suffering from Alzheimer's disease. By 2050, this number could reach more than 100 million. At present there is no cure for Alzheimer's disease, but treatments for symptoms, combined with the right services and support, can make life better for the millions of people living with Alzheimer's.

About the Piramal Group

The Piramal Group, led by Ajay G. Piramal, is one of India's foremost business conglomerates. Driven by the core values of Knowledge Action Care, the Piramal Group has interests in a myriad of industries that encompass healthcare, drug discovery & research, diagnostics, glass, real estate and financial services. The Piramal Group steadfastly pursues inclusive growth while adhering to ethical and value driven practices. The Group's turnover exceeded $ 900 million in FY2011.

About Piramal Healthcare Ltd

Piramal Healthcare is one of India's largest healthcare companies, with a growth track record of above 29% CAGR since 1988. Piramal Healthcare had consolidated revenues of $ 650 million in FY2011. With assets across North America, Europe and Asia, Piramal Healthcare is also one of the largest custom manufacturing companies across the world. It has significant presence in the global critical care space with sales of anesthesia products to over 100 countries. In 2010, Piramal Healthcare sold its domestic formulation business to Abbott for a consideration of US $ 3.8 billion.

For more information, please visit www.piramalhealthcare.com.


'/>"/>
SOURCE Piramal Healthcare Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
2. SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease
3. Stimatix GI Reports Encouraging Interim Results
4. AFFiRiS AG - Encouraging Results From Phase I Studies of two Alzheimers Candidate Vaccines Trigger a EUR 10 Million Milestone Payment
5. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
6. Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer
7. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
8. Encouraging Gene Therapy Results in Genetic Form of Blindness
9. Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO
10. Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
11. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 17, 2017 On Thursday, February ... edged lower at the closing bell, while the Dow ... 20,000 benchmark. Moreover, five out of nine sectors ended ... yesterday,s market sentiment, Stock-Callers.com assessed the following Medical Appliances ... (NYSE: SNN ), ABIOMED Inc. (NASDAQ: ...
(Date:2/16/2017)... Quest Diagnostics (NYSE: DGX ), ... announced that it has been named one of the ... The annual survey designated Quest Diagnostics as ... Pharmacy and Other Services" industry to attain Most Admired ... attain the designation. This is the second consecutive year ...
(Date:2/16/2017)... Conn. , Feb. 16, 2017 The Lockwood ... the 2017 Best Place to Work in Connecticut ... This is the third year in a row that Lockwood ... this year to earn the number-two spot in 2017. The ... maintaining workplace excellence. The winners were determined through a survey ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... The Alliance Healthcare Foundation ... to further positively impact the health and wellness of our community in San ... our duty to seriously consider releasing our assets beyond our 5% targeted distribution ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... and Reimbursement , **An FDAnews Webinar**, Feb. 22, 2017 — 1:30 p.m. ... critical reimbursement questions manufacturers should be asking before selecting an FDA approval ...
(Date:2/17/2017)... ... February 17, 2017 , ... Qualis Health, one ... in the 8th Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare ... is recognized across multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... announced today that Karen Pilley has been promoted to Chief Executive Officer. ... shifting healthcare paradigm – a shift that demands the transition from pay-for-service to ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... sponsor and exhibitor at Molecular Medicine Tri-Conference February 20 – 22 in San ... Inspirata will showcase its anatomic and molecular pathology workflow solution, as well as ...
Breaking Medicine News(10 mins):